CytoMed Therapeutics Ltd — Form SCHEDULE 13D/A
Filed July 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
A Schedule 13D/A (amended beneficial ownership statement) was filed on 2026-07-24 for CytoMed Therapeutics Ltd by filer Choo Chee Kong. The filing document itself is not provided in the text—only metadata (accession number, dates, addresses, SIC code) appears. No specific changes to ownership percentages, share counts, dollar amounts, or beneficial interest are disclosed in the available text.
Why this rating
Schedule 13D/A amendment is routine disclosure; actual amendment details (ownership %, shares, changes) absent from text. Cannot assess materiality without substance.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.